Equities research analysts predict that VERONA PHARMA P/S (NASDAQ:VRNA) will report earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for VERONA PHARMA P/S’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.67). VERONA PHARMA P/S reported earnings of ($0.64) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 21.9%. The business is expected to announce its next earnings results on Tuesday, February 26th.

Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover VERONA PHARMA P/S.

VERONA PHARMA P/S (NASDAQ:VRNA) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.26.

A number of equities analysts have commented on the stock. Jefferies Financial Group restated a “buy” rating and issued a $26.00 target price on shares of VERONA PHARMA P/S in a research note on Friday, August 10th. Wedbush reiterated a “buy” rating and set a $56.00 price objective on shares of VERONA PHARMA P/S in a research note on Wednesday, September 19th. Zacks Investment Research upgraded shares of VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective on the stock in a research note on Friday, August 24th. Finally, ValuEngine downgraded shares of VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. VERONA PHARMA P/S has an average rating of “Buy” and an average target price of $31.33.

An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC acquired a new stake in shares of VERONA PHARMA P/S (NASDAQ:VRNA) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S makes up about 0.0% of Foresite Capital Management IV LLC’s investment portfolio, making the stock its 21st largest position. Foresite Capital Management IV LLC owned 0.06% of VERONA PHARMA P/S as of its most recent SEC filing. Institutional investors and hedge funds own 56.23% of the company’s stock.

VERONA PHARMA P/S stock opened at $10.90 on Tuesday. The stock has a market capitalization of $153.16 million, a P/E ratio of -4.52 and a beta of -1.37. VERONA PHARMA P/S has a 1-year low of $10.19 and a 1-year high of $25.55.

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Further Reading: Market Capitalization in the Stock Market

Get a free copy of the Zacks research report on VERONA PHARMA P/S (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.